<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935453</url>
  </required_header>
  <id_info>
    <org_study_id>OrienGene-01</org_study_id>
    <nct_id>NCT01935453</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer</brief_title>
  <official_title>A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrienGene Biotechnology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>START Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Bozhiyin T&amp;S Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OrienGene Biotechnology Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds
      of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exploring the MTD of OrienX010 according to DLT,which defined as the serious degree of adverse events relates to the medicine not less than grade 3 of CTCAE v4.03</measure>
    <time_frame>28 days after the last administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Using RECIST 1.1 to evaluate the preliminary efficacy of OrienX010</measure>
    <time_frame>28 days after the last administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Melanoma</condition>
  <condition>Liver Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Recombinant HSV-1 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral injection Single dose: 4 groups -- 106 pfu, 107 pfu, 108 pfu and 4×108 pfu Multiple dose (three injections, every 2 weeks): 2 groups -- 108, 108, 108pfu and 4×108, 4×108, 4×108pfu Continuous treatment: Upon 4 weeks follow-up after administration, if the investigator deems that continuous treatment will benefit subjects, continuous intratumoral injection may be given, and the interval between each injection will be 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant hGM-CSF Herpes Simplex Virus Injection</intervention_name>
    <arm_group_label>Recombinant HSV-1 Injection</arm_group_label>
    <other_name>OrienX010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients in advanced stage of malignant tumor diagnosticated by pathologic and
             cytological analysis.

          -  lack of routine effective treatment,failure of routine treatment or relapse

          -  age of 18-70,ECOG 0-2 and estimated survival is above 3 months

          -  had an interval of above 4 weeks since exposure to chemotherapy or radiotherapy and
             above 6 weeks since exposure to nitrosoureas or mitomycin C.

        Exclusion Criteria:

          -  Serious internal diseases

          -  uncontrolled primary and metastatic brain tumor

          -  sizes of tumor does not meet the requirement of injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Ren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Shijitan Hospital,CMU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital,CMU</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

